These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23732986)

  • 1. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
    Ousterout DG; Perez-Pinera P; Thakore PI; Kabadi AM; Brown MT; Qin X; Fedrigo O; Mouly V; Tremblay JP; Gersbach CA
    Mol Ther; 2013 Sep; 21(9):1718-26. PubMed ID: 23732986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
    Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
    Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
    Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
    Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs.
    Zeng B; Zhou M; Liu B; Shen F; Xiao R; Su J; Hu Z; Zhang Y; Gu A; Wu L; Liu X; Liang D
    Biochem Biophys Res Commun; 2021 Mar; 545():40-45. PubMed ID: 33540285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meganucleases can restore the reading frame of a mutated dystrophin.
    Chapdelaine P; Pichavant C; Rousseau J; Pâques F; Tremblay JP
    Gene Ther; 2010 Jul; 17(7):846-58. PubMed ID: 20393509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endonucleases: tools to correct the dystrophin gene.
    Rousseau J; Chapdelaine P; Boisvert S; Almeida LP; Corbeil J; Montpetit A; Tremblay JP
    J Gene Med; 2011 Oct; 13(10):522-37. PubMed ID: 21954090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
    Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
    Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
    Duchêne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL
    Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse.
    Amoasii L; Li H; Zhang Y; Min YL; Sanchez-Ortiz E; Shelton JM; Long C; Mireault AA; Bhattacharyya S; McAnally JR; Bassel-Duby R; Olson EN
    Nat Commun; 2019 Oct; 10(1):4537. PubMed ID: 31586095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
    Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
    Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
    Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
    Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.